APRE_OUT_1 [2025-04-29 08:04:54 -0400] 5900 Bytes | 1646 tokens | Cum: 1646 tkns (20.57% of 8k)
==========================================================================

A volatile market is a logical market. It is 8:04 AM on Tue Apr 29, 2025. Aprea Therapeutics (APRE) surges from $1.59 to $1.75. Analyze we shall, without fear or favor.

--- COMPANY PROFILE ---
Company: Aprea Therapeutics (APRE)
IPO: 2019-10-03 (5 Years Ago)
Market Cap: $8,073,171
Shares Outstanding: 5,530,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Here’s a list of headlines for Aprea Therapeutics:

Apr-17-25 07:00AM - Adicet Bio Appoints Michael Grissinger to the Board of Directors
Apr-01-25 08:49AM - Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial
Mar-31-25 08:30AM - Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
Mar-25-25 08:30AM - Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Mar-11-25 08:30AM - Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
Feb-06-25 08:16AM - Aprea Therapeutics provides update on existing patent portfolio
Feb-05-25 08:00AM - Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
Dec-11-24 08:30AM - Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
Nov-13-24 09:55AM - Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher
Nov-07-24 09:20AM - Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates
Nov-07-24 09:20AM 08:00AM - Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Oct-24-24 08:40AM - Aprea Therapeutics presents preliminary results on APR-1051
Oct-23-24 08:30AM - Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
Oct-14-24 08:30AM - Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
Oct-10-24 07:03PM - Stonepine Capital Management, LLC Increases Stake in Aprea Therapeutics Inc
Oct-10-24 07:03PM 08:30AM - Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
Oct-09-24 08:30AM - Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
Sep-25-24 08:00AM - Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
Sep-20-24 08:35AM - Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Sep-16-24 12:07PM - Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Sep-12-24 08:30AM - Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19
Sep-09-24 05:15PM - UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-06-21T12:00:00Z - Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
B2 - 2024-06-17T12:30:00Z - Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
B3 - 2024-05-28T12:45:00Z - Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
B4 - 2024-05-13T20:01:00Z - Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
B5 - 2024-05-02T13:15:00Z - Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
B6 - 2024-04-10T16:00:00Z - Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Aprea Therapeutics (APRE).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

APRE_OUT_3 [2025-04-29 08:04:55 -0400] 722 Bytes | 224 tokens | Cum: 1872 tkns (23.40% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/06/17/2899646/0/en/Aprea-Therapeutics-Announces-First-Patient-Dosed-in-ACESOT-1051-Phase-1-Trial-Evaluating-Oral-WEE1-Inhibitor-APR-1051.htmlAPR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APRE_OUT_5 [2025-04-29 08:04:55 -0400] 911 Bytes | 288 tokens | Cum: 2162 tkns (27.02% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-17T14:05:21Z - APRE stock touches 52-week low at $1.5 amid market challenges By Investing.com...
A2 - 2025-04-17T11:26:52Z - Adicet Bio (ACET) Appoints Michael Grissinger to the Board of Directors...
A3 - 2025-04-05T10:33:58Z - Aprea Therapeutics, Inc. (NASDAQ:APRE) CEO Purchases $10,120.00 in Stock...
A4 - 2025-04-04T11:32:10Z - Aprea Therapeutics CEO Gilad Oren acquires $10,110 in stock By Investing.com...
A5 - 2025-03-31T15:29:00Z - Aprea Therapeutics Doses First Patient With HPV+ HNSCC In ACESOT-1051 Trial...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

APRE_OUT_7 [2025-04-29 08:04:57 -0400] 1181 Bytes | 306 tokens | Cum: 2470 tkns (30.88% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**APRE stock touches 52-week low at $1.5 amid market challenges By Investing.com**Date: 2025-04-17Source: {'uri': 'investing.com', 'dataType': 'news', 'title': 'Investing.com'}URL: https://www.investing.com/news/company-news/apre-stock-touches-52week-low-at-15-amid-market-challenges-93CH-3991172In a challenging market environment, Aprea Therapeutics Inc (NASDAQ:APRE)'s stock has reached a 52-week low, trading at $1.5, with a market capitalization of just $8.35 million. According to InvestingPro analysis, the stock's RSI indicates oversold conditions, suggesting potential for a technical rebound. This significant downturn reflects a broader trend for the biopharmaceutical company, which has seen its shares plummet by -72.91% over the past year. Investors are closely monitoring APRE as it navigates through a period marked by volatility and uncertainty within the biotech sector. Investi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APRE_OUT_9 [2025-04-29 08:04:57 -0400] 1181 Bytes | 271 tokens | Cum: 2743 tkns (34.29% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): ngPro data shows analyst price targets ranging from $10 to $20, though the company maintains a "Fair" financial health score of 2.01 out of 5. The 52-week low serves as a critical juncture for Aprea Therapeutics, as market participants consider the company's strategic moves to recover value and regain momentum in its stock price. Based on InvestingPro's Fair Value analysis, the stock appears undervalued at current levels, with 12 additional ProTips available for subscribers.

In other recent news, Aprea Therapeutics has announced a collaboration with MD Anderson Cancer Center to advance research on a potential new cancer treatment. This partnership will focus on preclinical studies of Aprea's WEE1 kinase inhibitor, APR-1051, specifically targeting head and neck squamous cell carcinoma. The research aims to explore the efficacy of APR-1051, particularly in combination with immune checkpoi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APRE_OUT_11 [2025-04-29 08:04:58 -0400] 1060 Bytes | 232 tokens | Cum: 2977 tkns (37.21% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): nt inhibitors, and could pave the way for future clinical trials. In addition, Aprea Therapeutics has expanded its patent portfolio, which includes four granted U.S. patents and several international patents related to its ATR inhibitor program. This program features the lead compound ATRN-119, currently undergoing clinical trials for advanced solid tumors. The company may see patent exclusivity extend into the 2040s, with potential regulatory exclusivities adding further protection. Aprea's intellectual property also covers the WEE1 kinase inhibitor program, including APR-1051, which is in a Phase 1 trial for advanced solid tumors. These developments underscore Aprea's strategy to enhance its oncology treatment offerings while safeguarding its intellectual property.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APRE_OUT_13 [2025-04-29 08:04:59 -0400] 1093 Bytes | 278 tokens | Cum: 3257 tkns (40.71% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S4 - 2025-03-25 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis of financial condition and results of operations is provided to enhance the understanding of, and should be read in conjunction with Part I, Item ...

S5 - 2025-03-25 8-K Item 2.02 Results of Oper and Fin Cond.

On March 25, 2025, Aprea Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the three and twelve months ended December 31, 2024, and provided an update on the Companys operations ...

S6 - 2025-01-13 8-K Item 2.02 Results of Oper and Fin Cond.

On January 13, 2025, Aprea Therapeutics, Inc. (the Company) posted an updated corporate presentation slide deck (the Corporate Presentation) to its website. In the Corporate Presentation, the Company disclosed that, as of...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

APRE_OUT_15 [2025-04-29 08:05:00 -0400] 1181 Bytes | 257 tokens | Cum: 3516 tkns (43.95% of 8k)
==========================================================================

Showing S4 (chunk 1 of 6): S4:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of financial condition and results of operations is provided to enhance the understanding of, and should be read in conjunction with Part I, Item I, Business and Item 8, Financial Statements and Supplementary Data. For information on risks and uncertainties related to our business that may make past performance not indicative of future results or cause actual results to differ materially from any forward-looking statements, see Special Note Regarding Forward-Looking Statements, and Part I, Item 1A, Risk Factors.

Overview

We are a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. Prior to the acquisition of Atrin Pharmaceuticals Inc. (Atrin) in May 2022, we were engaged in the clinical development of

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APRE_OUT_17 [2025-04-29 08:05:01 -0400] 1181 Bytes | 242 tokens | Cum: 3760 tkns (47.00% of 8k)
==========================================================================

Showing S4 (chunk 2 of 6): cancer therapeutics that reactivate the mutant p53 tumor suppressor protein. Following our acquisition of Atrin, we shifted the focus of our activities to the assets acquired from Atrin. Our approach is built upon a platform of integrated discovery technologies to enrich our pipeline with novel targets in synthetic lethality and cancer treatment. Together with our expertise in small molecule drug discovery, we are applying the capabilities of our discovery platform to the development of new precision oncology therapies and the identification of patient populations most likely to benefit.

We believe that synthetic lethality has the potential to impact patients lives and treatment strategies for a wide range of cancer types. We aspire to become a leader in this emerging field and are establishing a pipeline of clinical and preclinical programs that we believe may have broad application t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APRE_OUT_19 [2025-04-29 08:05:01 -0400] 1181 Bytes | 299 tokens | Cum: 4061 tkns (50.76% of 8k)
==========================================================================

Showing S4 (chunk 3 of 6): o cancer treatment.

We are targeting WEE1, a kinase that is a key regulator of multiple phases of the cell cycle. Our lead WEE1 inhibitor product candidate is APR-1051. In March 2024, the FDA cleared our IND application for APR-1051 and in the second quarter of 2024 we enrolled the first patient into ACESOT-1051, our Phase 1 dose escalation study. We anticipate open-label safety/efficacy data to be available in the second half of 2025. We expect to complete dose-escalation in the first half of 2026.

Our second clinical-stage synthetic lethality product candidate is ATRN-119, an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR. The ATR kinase is master regulator of the DNA damage response, with key roles in cell cycle control and DNA repair following replication stress. We have developed ATRN-119, the first oral macrocyclic ATR inhibitor to enter clinica

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APRE_OUT_21 [2025-04-29 08:05:02 -0400] 1181 Bytes | 279 tokens | Cum: 4342 tkns (54.27% of 8k)
==========================================================================

Showing S4 (chunk 4 of 6): l trials. We are enrolling patients into ABOYA-119, a Phase 1/2a clinical trial to evaluate ATRN-119 under an IND application. The first six dose cohorts have been completed with the seventh cohort currently enrolling. The primary endpoint of this Phase 1 part is to evaluate the tolerability and pharmacokinetics of ATRN-119 when administered orally on a continuous schedule. We anticipate ATRN-119 Phase 1 readout to be available in the second half of 2025 and to determine the Recommended Phase 2 Dose (RP2D) in Q1 2026.

In addition to development of these drugs as single agents, we are evaluating potential expansion opportunities for our product candidates through combination with other agents such as poly (ADP-ribose) polymerase inhibitors, or PARPi, where we believe a combination of therapeutic agents may enhance synthetic lethality. We are also evaluating combination opportunities with

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APRE_OUT_23 [2025-04-29 08:05:03 -0400] 1181 Bytes | 257 tokens | Cum: 4601 tkns (57.51% of 8k)
==========================================================================

Showing S4 (chunk 5 of 6): in our pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute.

In addition, we also have an early preclinical research program, which is currently in the lead optimization stage, for an undisclosed DDR target. We do not currently have any ongoing preclinical studies or clinical trials involving our reactivators of mutant p53 and our primary focus is on the discovery and development of molecules targeting DDR pathways in oncology through synthetic lethality.

We have assembled a team with extensive experience in the discovery, development and commercialization of oncology drugs to support our mission of developing novel synthetic lethality-based cancer therapeutics.

Corporate Background

Aprea Therapeutics AB, or Aprea AB, was originally incorporated in 2002 and commenced principal operatio

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APRE_OUT_25 [2025-04-29 08:05:04 -0400] 790 Bytes | 195 tokens | Cum: 4798 tkns (59.98% of 8k)
==========================================================================

Showing S4 (chunk 6 of 6): ns in 2006. We incorporated Aprea Therapeutics, Inc. (the Company) in May 2019. In September 2019 we completed a corporate reorganization and, as a result, all of the issued and outstanding stock of Aprea AB was exchanged for common stock, preferred stock or options, as applicable, of the Company. As a result of such transactions, Aprea AB became a wholly-owned subsidiary of the Company.

We have devoted substantially all of our resources to developing our product candidates, building our intellectu...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APRE_OUT_27 [2025-04-29 08:05:10 -0400] 6508 Bytes | 1801 tokens | Cum: 6601 tkns (82.51% of 8k)
==========================================================================

This is our set of metrics for Aprea Therapeutics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+------------------------+
| Volume: 83,781 | Perf Month: -20.45% | Option/Short: No / Yes | Sales Y/Y TTM: 157.63% |
+--------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 27.73K | Perf Quarter: -53.33% | Short Float: 1.25% | ROE: -66.65% |
+--------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 3.16 | Index: - | Short Ratio: 2.18 | ROI: -62.85% |
+--------------------+-----------------------+------------------------+------------------------+
| RSI (14): 46.18 | Market Cap: 9.67M | Short Interest: 0.06M | Sales Surprise: -8.53% |
+--------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.15 | Shs Outstand: 5.48M | Beta: 1.19 | EPS Surprise: 25.76% |
+--------------------+-----------------------+------------------------+------------------------+
| SMA20: 6.32% | Shs Float: 4.82M | Sales Q/Q: 1362.29% | P/E: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA50: -19.11% | Inst Own: 37.58% | Sales past 5Y: 31.53% | Earnings: Mar 25 BMO |
+--------------------+-----------------------+------------------------+------------------------+
| SMA200: -44.57% | Insider Own: 12.73% | Employees: 8 | |
+--------------------+-----------------------+------------------------+------------------------+
| Perf Week: 19.05% | Insider Trans: 0.79% | Debt/Eq: 0.00 | |
+--------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading by Aprea Therapeutics officers or majority shareholders (if available).

Inside Trans: Aprea Therapeutics, Inc. (APRE) by Gilad Oren (President/CEO) on 2025-04-03
- Common Stock: 3003 shares at $1.87 (D)
- Common Stock: 2497 shares at $1.8 (D)

Inside Trans: Aprea Therapeutics, Inc. (APRE) by Gilad Oren (President/CEO) on 2025-03-27
- Common Stock: 6725 shares at $0 (D)
- Stock Options (Right to Buy): 26900 shares at $0 (D)

Inside Trans: Aprea Therapeutics, Inc. (APRE) by Hamill John P. (SrVP/CFO/Prin Fin & Acct Ofcr) on 2025-03-27
- Common Stock: 3365 shares at $0 (D)
- Stock Options (Right to Buy): 13460 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 1502581.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -12958711.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.75
Average Volume: 33650.4
30-Day High: 2.04
30-Day Low: 1.47

[Detailed Financials: TTM 2024]
- Total Assets: $23,979,493.00
- Total Liabilities: $4,672,038.00
- Total Equity: $19,307,455.00
- Current Assets: $23,576,139.00
- Current Liabilities: $3,360,975.00

[Income Statement: TTM 2024]
- Revenue: $1,502,581.00
- Net Income: $-12,958,711.00
- Gross Profit: N/A
- Operating Income: $-14,319,655.00
- Earnings Per Share (EPS): -2.35

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $1,249,699.00

[Detailed Financials: FY 2024]
- Total Assets: $23,979,493.00
- Total Liabilities: $4,672,038.00
- Total Equity: $19,307,455.00
- Current Assets: $23,576,139.00
- Current Liabilities: $3,360,975.00

[Income Statement: FY 2024]
- Revenue: $1,502,581.00
- Net Income: $-12,958,711.00
- Gross Profit: N/A
- Operating Income: $-14,319,655.00
- Earnings Per Share (EPS): -2.35

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $1,249,699.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Aprea Therapeutics (APRE).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Aprea Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because APRE is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for APRE.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, APRE could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect APRE to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Aprea Therapeutics.

11) ETHICAL_RATING[]
Rate Aprea Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Aprea Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

APRE_IN_29 [2025-04-29 08:05:10 -0400] 126 Bytes | 29 tokens | Cum: 6845 tkns (85.56% of 8k)
==========================================================================

====================================
[2025-04-29 08:05:10] # Analysis Completed
Elapsed Time: 17.24 seconds